Afya (NASDAQ:AFYA) Stock Price Target Lowered at JPMorgan Chase & Co.

Afya (NASDAQ:AFYA) had its price target reduced by equities researchers at JPMorgan Chase & Co. from $19.00 to $17.50 in a report issued on Tuesday, Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price would indicate a potential upside of 67.24% from the company’s previous close.

A number of other analysts have also commented on the stock. Weiss Ratings lowered shares of Afya from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday. Bradesco Corretora raised shares of Afya to an “outperform” rating and set a $17.00 price objective for the company in a report on Thursday, September 24th. Wall Street Zen downgraded shares of Afya from a “buy” rating to a “hold” rating in a research report on Saturday. Citigroup upgraded shares of Afya from a “neutral” rating to a “buy” rating and dropped their target price for the stock from $16.00 to $12.00 in a report on Tuesday. Finally, Zacks Research upgraded shares of Afya from a “strong sell” rating to a “hold” rating in a report on Monday, October 5th. Four equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $15.70.

Afya Stock Performance

NASDAQ AFYA traded down $0.18 during trading hours on Tuesday, hitting $10.46. The company’s stock had a trading volume of 124,441 shares, compared to its average volume of 190,302. Afya has a 12 month low of $9.66 and a 12 month high of $16.16. The company’s 50 day simple moving average is $13.55 and its two-hundred day simple moving average is $14.18. The company has a market cap of $980.72 million, a P/E ratio of 6.39, a price-to-earnings-growth ratio of 1.24 and a beta of 0.34. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.20 and a quick ratio of 2.20.

Afya (NASDAQ:AFYA) last issued its earnings results on Friday, August 14th. The company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.40 by $0.03. The business had revenue of $187.80 million during the quarter, compared to analyst estimates of $189.62 million. Afya had a return on equity of 17.58% and a net margin of 20.55%. As a group, sell-side analysts expect that Afya will post 1.72 EPS for the current fiscal year.

Insider Activity at Afya

In other news, insider Santos Welder Ferreira sold 4,161 shares of the stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $13.30, for a total value of $55,341.30. Following the transaction, the insider owned 35,000 shares in the company, valued at $465,500. This represents a 10.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.80% of the stock is owned by insiders.

Institutional Trading of Afya

A hedge fund recently bought a new position in Afya stock. Engineers Gate Manager LP purchased a new position in Afya Limited (NASDAQ:AFYA) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 21,882 shares of the company’s stock, valued at approximately $325,000. Hedge funds and other institutional investors own 88.02% of the company’s stock.

About Afya

Afya Limited is a medical education and digital health company focused on Brazil. Through its educational platform, the company provides undergraduate medical education, medical residency preparation, specialization and continuing medical education programs, and other learning resources for students and physicians.

Afya also offers digital products and services intended to support healthcare professionals throughout their careers. These include clinical content, study tools, telemedicine and practice-management solutions, and subscription-based applications designed to assist physicians with education, clinical decision-making, and patient care.

The company has expanded through the development and acquisition of medical schools, education businesses, and health technology platforms serving different stages of the medical professional lifecycle.